Chunyi Hao

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution

Shaoping Ling, Zheng Hu, Zuyu Yang et al. · Proceedings of the National Academy of Sciences · 2015 · 374 citations · Full text

Life Sciences, Evolutionary Biology, Genetics +14

Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis

Wei Sun, Baocai Xing, Yi Sun et al. · Molecular & Cellular Proteomics · 2007 · 246 citations · Full text

Medicine, Molecular Biology, Oncology +17

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Shukui Qin, Zhendong Chen, Weijia Fang et al. · Journal of Clinical Oncology · 2022 · 189 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial

Kanglian Zheng, Xu Zhu, Shijie Fu et al. · Radiology · 2022 · 154 citations

Medicine, Oncology, Pharmacotherapy +14